THAR News

Thar Pharmaceuticals, which is developing novel oral therapies for chronic pain utilizing the 505(b)(2) pathway, withdrew its plans for an initial public offering on Wednesday. It originally filed in August 2016 with a proposed deal size of $50 million. Competitor Axsome Therapeutics (AXSM; -18%) raised $51 million in a November 2015 IPO. The Pittsburgh,...read more

Just one small blank check company went public this past week, in the doldrums of the IPO market's annual summer slowdown. Stellar Acquisition III (STLRU), which raised $65 million in a downsized offering, is a Greece-based SPAC looking to acquire an energy logistics business, such as a tanker operator. We do not include SPACs in our IPO stats. The average...read more

Thar Pharmaceuticals, which is developing oral therapies for complex regional pain syndrome, filed on Friday with the SEC to raise up to $50 million in an initial public offering. The Pittsburgh, PA-based company was founded in 2006 and plans to list on the Nasdaq under the symbol THAR. SunTrust Robinson Humphrey is the sole bookrunner on the deal. No pricing terms were...read more